 Vivekanand Yadav
Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioma | 9 | 2022 | 9 | 2.540 |
Why?
| | Brain Neoplasms | 9 | 2022 | 27 | 2.240 |
Why?
| | Viral Proteins | 5 | 2017 | 19 | 1.180 |
Why?
| | Endothelial Cells | 2 | 2018 | 15 | 0.890 |
Why?
| | Vaccinia virus | 3 | 2017 | 4 | 0.880 |
Why?
| | Receptors, CXCR4 | 2 | 2016 | 4 | 0.820 |
Why?
| | Glioblastoma | 2 | 2016 | 8 | 0.810 |
Why?
| | Animals | 14 | 2022 | 884 | 0.780 |
Why?
| | Bevacizumab | 1 | 2018 | 1 | 0.740 |
Why?
| | Radiation, Ionizing | 1 | 2018 | 1 | 0.740 |
Why?
| | Thymidine Kinase | 1 | 2018 | 2 | 0.740 |
Why?
| | Ganciclovir | 1 | 2018 | 3 | 0.740 |
Why?
| | Simplexvirus | 1 | 2018 | 3 | 0.740 |
Why?
| | Complement Pathway, Alternative | 4 | 2017 | 4 | 0.710 |
Why?
| | Neoplastic Stem Cells | 2 | 2016 | 7 | 0.700 |
Why?
| | Apoptosis | 2 | 2016 | 64 | 0.680 |
Why?
| | RNA Interference | 1 | 2016 | 11 | 0.660 |
Why?
| | Gene Knockdown Techniques | 1 | 2016 | 15 | 0.650 |
Why?
| | Cell Movement | 1 | 2016 | 28 | 0.650 |
Why?
| | Complement C3b | 4 | 2012 | 4 | 0.620 |
Why?
| | Mice | 9 | 2022 | 441 | 0.600 |
Why?
| | Humans | 20 | 2022 | 5964 | 0.540 |
Why?
| | Complement System Proteins | 2 | 2009 | 5 | 0.460 |
Why?
| | Histones | 4 | 2022 | 31 | 0.440 |
Why?
| | Mutation | 5 | 2022 | 202 | 0.430 |
Why?
| | Tumor Cells, Cultured | 3 | 2020 | 25 | 0.400 |
Why?
| | Cell Line, Tumor | 6 | 2022 | 66 | 0.380 |
Why?
| | Variola virus | 1 | 2008 | 1 | 0.360 |
Why?
| | Amino Acid Sequence | 4 | 2017 | 68 | 0.270 |
Why?
| | Cell Proliferation | 3 | 2020 | 68 | 0.250 |
Why?
| | Mice, Inbred C57BL | 3 | 2022 | 130 | 0.250 |
Why?
| | Combined Modality Therapy | 2 | 2018 | 52 | 0.220 |
Why?
| | Molecular Sequence Data | 3 | 2012 | 120 | 0.220 |
Why?
| | Static Electricity | 2 | 2012 | 3 | 0.220 |
Why?
| | Angiogenesis Inhibitors | 2 | 2018 | 2 | 0.220 |
Why?
| | Signal Transduction | 3 | 2016 | 150 | 0.220 |
Why?
| | Mice, Transgenic | 2 | 2018 | 52 | 0.220 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 21 | 0.220 |
Why?
| | Dasatinib | 1 | 2020 | 1 | 0.220 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2020 | 31 | 0.220 |
Why?
| | Everolimus | 1 | 2020 | 2 | 0.220 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2020 | 3 | 0.220 |
Why?
| | Brain Stem Neoplasms | 1 | 2020 | 1 | 0.210 |
Why?
| | Amino Acid Substitution | 2 | 2012 | 10 | 0.210 |
Why?
| | Epigenomics | 1 | 2020 | 25 | 0.210 |
Why?
| | Spinal Cord Neoplasms | 1 | 2020 | 3 | 0.210 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2020 | 3 | 0.210 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 61 | 0.200 |
Why?
| | Neoplasm Invasiveness | 2 | 2016 | 8 | 0.200 |
Why?
| | Survival Rate | 1 | 2018 | 79 | 0.180 |
Why?
| | Antiviral Agents | 1 | 2018 | 23 | 0.180 |
Why?
| | Complement Pathway, Classical | 1 | 2017 | 1 | 0.170 |
Why?
| | Viral Tropism | 1 | 2017 | 1 | 0.170 |
Why?
| | Viral Matrix Proteins | 1 | 2017 | 2 | 0.170 |
Why?
| | Complement Activation | 1 | 2017 | 2 | 0.170 |
Why?
| | Genetic Vectors | 2 | 2015 | 7 | 0.170 |
Why?
| | Cancer Vaccines | 1 | 2017 | 1 | 0.170 |
Why?
| | Genetic Therapy | 1 | 2017 | 3 | 0.170 |
Why?
| | Female | 4 | 2022 | 3320 | 0.170 |
Why?
| | Immunotherapy | 1 | 2017 | 15 | 0.170 |
Why?
| | Inflammation | 2 | 2015 | 43 | 0.170 |
Why?
| | Radiation Tolerance | 1 | 2016 | 1 | 0.170 |
Why?
| | Coculture Techniques | 1 | 2016 | 3 | 0.170 |
Why?
| | Tumor Burden | 1 | 2016 | 5 | 0.170 |
Why?
| | Species Specificity | 2 | 2017 | 8 | 0.160 |
Why?
| | Transfection | 1 | 2016 | 32 | 0.160 |
Why?
| | Cattle | 2 | 2017 | 26 | 0.160 |
Why?
| | Chemokine CXCL12 | 1 | 2016 | 1 | 0.160 |
Why?
| | Sequence Alignment | 3 | 2017 | 13 | 0.150 |
Why?
| | Time Factors | 1 | 2016 | 269 | 0.150 |
Why?
| | Ubiquitin-Conjugating Enzymes | 1 | 2015 | 1 | 0.150 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2015 | 2 | 0.150 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2015 | 9 | 0.140 |
Why?
| | Haemophilus Infections | 1 | 2015 | 5 | 0.140 |
Why?
| | Respiratory System | 1 | 2015 | 5 | 0.140 |
Why?
| | Protein Binding | 3 | 2015 | 49 | 0.140 |
Why?
| | Carrier Proteins | 1 | 2015 | 35 | 0.140 |
Why?
| | Membrane Proteins | 1 | 2015 | 54 | 0.140 |
Why?
| | Galectin 1 | 1 | 2014 | 1 | 0.140 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2014 | 8 | 0.140 |
Why?
| | Killer Cells, Natural | 1 | 2014 | 11 | 0.140 |
Why?
| | Neovascularization, Pathologic | 1 | 2014 | 4 | 0.140 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2014 | 16 | 0.140 |
Why?
| | Dependovirus | 1 | 2014 | 1 | 0.140 |
Why?
| | Antigen-Presenting Cells | 1 | 2014 | 2 | 0.140 |
Why?
| | Central Nervous System | 1 | 2014 | 7 | 0.140 |
Why?
| | Complement C4b | 3 | 2009 | 3 | 0.130 |
Why?
| | Imidazoles | 1 | 2022 | 2 | 0.120 |
Why?
| | Pyrimidines | 1 | 2022 | 3 | 0.120 |
Why?
| | Complement Factor I | 1 | 2012 | 1 | 0.120 |
Why?
| | Pyridines | 1 | 2022 | 13 | 0.120 |
Why?
| | Immune Evasion | 1 | 2012 | 3 | 0.120 |
Why?
| | Herpesvirus 8, Human | 2 | 2010 | 2 | 0.120 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2010 | 20 | 0.110 |
Why?
| | Complement Inactivator Proteins | 1 | 2010 | 1 | 0.100 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2009 | 3 | 0.100 |
Why?
| | Tryptophan | 1 | 2009 | 4 | 0.100 |
Why?
| | Herpesvirus 2, Saimiriine | 1 | 2009 | 1 | 0.100 |
Why?
| | Child | 2 | 2022 | 2796 | 0.100 |
Why?
| | Molecular Targeted Therapy | 2 | 2020 | 13 | 0.090 |
Why?
| | Surface Plasmon Resonance | 1 | 2008 | 1 | 0.090 |
Why?
| | Models, Molecular | 1 | 2008 | 18 | 0.090 |
Why?
| | Mice, Inbred NOD | 2 | 2020 | 7 | 0.090 |
Why?
| | Mice, Knockout | 2 | 2020 | 101 | 0.090 |
Why?
| | Antineoplastic Agents | 2 | 2020 | 44 | 0.080 |
Why?
| | Male | 2 | 2022 | 3237 | 0.060 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2022 | 4 | 0.060 |
Why?
| | Cell Cycle Checkpoints | 1 | 2022 | 4 | 0.060 |
Why?
| | Primary Cell Culture | 1 | 2022 | 6 | 0.060 |
Why?
| | Cell Cycle | 1 | 2022 | 14 | 0.060 |
Why?
| | Glycine | 1 | 2021 | 3 | 0.060 |
Why?
| | Drug Synergism | 1 | 2020 | 6 | 0.050 |
Why?
| | Epigenesis, Genetic | 1 | 2021 | 81 | 0.050 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2020 | 4 | 0.050 |
Why?
| | Transplantation, Heterologous | 1 | 2020 | 6 | 0.050 |
Why?
| | Lysine | 1 | 2020 | 6 | 0.050 |
Why?
| | Glycolysis | 1 | 2020 | 4 | 0.050 |
Why?
| | Mice, SCID | 1 | 2020 | 11 | 0.050 |
Why?
| | Methylation | 1 | 2020 | 17 | 0.050 |
Why?
| | Mice, Nude | 1 | 2020 | 16 | 0.050 |
Why?
| | Gene Expression | 1 | 2020 | 74 | 0.050 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2020 | 5 | 0.050 |
Why?
| | Immunotherapy, Adoptive | 1 | 2020 | 6 | 0.050 |
Why?
| | Cerebrospinal Fluid | 1 | 2020 | 8 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 50 | 0.050 |
Why?
| | Pregnancy | 1 | 2020 | 252 | 0.050 |
Why?
| | Prognosis | 1 | 2020 | 179 | 0.050 |
Why?
| | Fibrinogen | 1 | 2017 | 1 | 0.040 |
Why?
| | Complement C4b-Binding Protein | 1 | 2017 | 1 | 0.040 |
Why?
| | Protein Structure, Tertiary | 2 | 2009 | 17 | 0.040 |
Why?
| | Recombinant Proteins | 2 | 2009 | 67 | 0.040 |
Why?
| | Dacarbazine | 1 | 2017 | 1 | 0.040 |
Why?
| | Transposases | 1 | 2016 | 1 | 0.040 |
Why?
| | Cell Hypoxia | 1 | 2016 | 2 | 0.040 |
Why?
| | Neural Stem Cells | 1 | 2016 | 8 | 0.040 |
Why?
| | Child, Preschool | 1 | 2020 | 1442 | 0.040 |
Why?
| | Ubiquitination | 1 | 2015 | 5 | 0.040 |
Why?
| | Lentivirus | 1 | 2015 | 3 | 0.040 |
Why?
| | Haemophilus influenzae | 1 | 2015 | 4 | 0.040 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2015 | 2 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2015 | 32 | 0.040 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2015 | 10 | 0.040 |
Why?
| | Immunologic Surveillance | 1 | 2014 | 1 | 0.040 |
Why?
| | Adaptive Immunity | 1 | 2014 | 6 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2014 | 35 | 0.030 |
Why?
| | Biopsy | 1 | 2014 | 55 | 0.030 |
Why?
| | Adolescent | 1 | 2020 | 1931 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2014 | 80 | 0.030 |
Why?
| | Disease Progression | 1 | 2014 | 93 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 140 | 0.030 |
Why?
| | Models, Biological | 1 | 2014 | 53 | 0.030 |
Why?
| | Rats | 1 | 2014 | 208 | 0.030 |
Why?
| | Algorithms | 1 | 2014 | 96 | 0.030 |
Why?
| | Brain | 1 | 2014 | 90 | 0.030 |
Why?
| | Protein Denaturation | 1 | 2009 | 1 | 0.030 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2009 | 1 | 0.030 |
Why?
| | Circular Dichroism | 1 | 2009 | 3 | 0.030 |
Why?
| | Fluorescence | 1 | 2009 | 6 | 0.030 |
Why?
| | Protein Conformation | 1 | 2009 | 10 | 0.030 |
Why?
| | Cloning, Molecular | 1 | 2009 | 31 | 0.030 |
Why?
| | Biotinylation | 1 | 2009 | 1 | 0.020 |
Why?
| | Lectins | 1 | 2009 | 2 | 0.020 |
Why?
| | Ligands | 1 | 2009 | 8 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2009 | 18 | 0.020 |
Why?
| | Kinetics | 1 | 2009 | 36 | 0.020 |
Why?
| | Gene Deletion | 1 | 2009 | 18 | 0.020 |
Why?
| | Heparin | 1 | 2005 | 7 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 99 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Physical Neighbors People whose addresses are nearby this person. _
|